Skip to Content

Risankizumab Downregulates IL-23-Induced Mucosal Pathogenic Th17 Cells in Patients with Crohn’s Disease

This study, presented by Daniele Noviello, a gastroenterologist and PhD student at the University of Milan, focuses on the impact of different biological therapies on a subset of Th17 cells, known as pathogenic Th17 (pTh17) cells, in patients with Crohn’s disease. The research demonstrates that Risankizumab, unlike Ustekinumab or Vedolizumab, effectively downregulates IL-23-induced mucosal pTh17 cells in these patients.

Daniele Noviello

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top